RVTY Revvity
FY2025 10-K
Revvity (RVTY) filed its fiscal year 2025 10-K annual report with the SEC on Feb 24, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Health science solutions provider across two segments (Life Sciences and Diagnostics), serving drug discovery through clinical diagnostics in 160+ countries
- • Notable new products in FY2025: Phenologic.AI™ deep-learning imaging module, EnVision Nexus® plate reader, NeoLSD™ 7 Plex MS/MS kit (first IVD for 7 lysosomal disorders from single blood spot), and T-SPOT.Flex™ customizable ELISPOT kit
Management Discussion & Analysis
- • Revenue $2,856.1M in FY2025, up $101.1M (+4%) YoY; Diagnostics +5% ($68.5M), Life Sciences +2% ($32.5M)
- • Gross margin 54.8% vs 55.8%; operating margin decreased 10 bps; SG&A ratio 34.7% vs 36.1%
Risk Factors
- • Tariffs imposed in fiscal year 2025 increased cost of revenue by ~$25M and reduced gross margin by ~$20M, primarily on European-manufactured products sold in U.S.
- • U.S. government funding uncertainty causing cautious customer spending on instrumentation and consumables across pharma, biotech, and academic segments
Financial SummaryXBRL
Revenue
$2.9B
Net Income
$241M
Operating Margin
12.5%
Net Margin
8.4%
ROE
3.3%
Total Assets
$12.2B
EPS (Diluted)
$2.07
Operating Cash Flow
$583M
Source: XBRL data from Revvity FY2025 10-K filing on SEC EDGAR. All figures in USD.
Other Revvity Annual Reports
Get deeper insights on Revvity
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.